CAMBRIDGE, Mass. (TheStreet) -- While some biotech investors like to play the "run up" to clinical data or FDA drug approval decisions, others may be more inclined to take the risk and hold through these important binary events. This more traditional approach to biotech investing requires a careful, fundamental analysis that weighs the odds of a positive or negative outcome against the upside rewards or downside risks in the stock price.
Obviously, the key to profiting from binary-event investing is to find a stock where the potential rewards outweigh the possible risks. I believe I've found one such situation with the publicly traded, contingent value rights (CVR) tied to the cancer drug Abraxane. Celgene (CELG) created these CVRs when it acquired Abraxane's original owner Abraxis BioScience in 2010.
This Celgene CVR (CELGZ) closed Monday at $2.50. What I like about the Celgene CVR is the potential for a nearly $7.50-per-share payout should a phase III study of Abraxane in pancreatic cancer succeed.
Abraxane is an albumin-bound formulation of paclitaxel, the old cancer chemotherapy drug. Abraxane is currently approved to treat breast cancer and does seem to be more efficacious and less toxic than standard paclitaxel. Celgene is seeking an expanded FDA approval for Abraxane into non-small cell lung cancer and has other late-stage studies ongoing, including melanoma and the above-mentioned pancreatic cancer.Gemcitabine is the current standard of care in pancreatic cancer, which generally conveys a survival benefit of approximately six months. Despite many attempts, pancreatic cancer has been stubbornly resistant to new therapies. Pancreatic cancer cells are believed to be surrounded by what amounts to a protective shell. This shell makes it very difficult for cancer-killing drugs to penetrate effectively. Abraxane and its albumin formulation may have stumbled upon a way to weaken the coat of armor that normally protects pancreatic cancer cells. In phase II studies, Abraxane demonstrated a median overall survival of 12.2 months and conferred an even longer survival rate in patients with pancreatic tumors expressing high levels of a protein known as SPARC. [Approximately half of all pancreatic tumors over-express SPARC.] On the downside, the Abraxane phase II studies were single arm, therefore lacking a comparator. However, the studies were conducted in the U.S., which mitigates some of the added risk.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV